The change in FIB-4 in Japanese patients with type 2 diabetes treated by a fixed-ratio combination therapy of insulin degludec and liraglutide (IDegLira)

The change in FIB-4 in Japanese patients with type 2 diabetes treated by a fixed-ratio combination therapy of insulin degludec and liraglutide (IDegLira) - The change in FIB-4 in Japanese patients with type 2 diabetes treated by a fixed-ratio combination therapy of insulin degludec and liraglutide (IDegLira)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051180

Enrollment

100

Registered

2023-05-28

Start date

2020-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who were continued IDegLira therapy for more than 6 months

Exclusion criteria

Exclusion criteria: IDegLira was started at dose >16 dose steps IDegLira had already been administered at the initial consultation Antidiabetic agents other than IDegLira were changed during observation period Patients who discontinued treatment during observation period Patients who were transport to other hospitals during observation period

Design outcomes

Primary

Measure	Time frame
The change in FIB-4 during 6 months of observation after the initiation of IDegLira	—

Secondary

Measure	Time frame
The changes in the HbA1c value and body weight and the adverse events	—

Countries

Japan

Contacts

Public ContactHiroyuki Ito

Edogawa Hospital Department of Diabetes, Metabolism and Kidney Disease

ito@edogawa.or.jp03-3673-1221

Outcome results